This study involves children with autism spectrum disorder who also experience ongoing problems with their digestive system, such as stomach pain, diarrhea, or constipation. The treatment being tested uses special cells called mesenchymal stem cells that come from fatty tissue. These cells are obtained from donors, meaning they come from another person rather than the patient themselves. The study will test two different preparations of these cells, known as C2C_ASC66 and C2C_ASC110. Both preparations contain the same type of cells and will be given through an infusion, which means the cells will be delivered directly into the bloodstream through a vein, similar to receiving fluids in a hospital.
The purpose of this study is to check whether this cell treatment is safe for children with autism and digestive problems. The researchers want to carefully monitor any unwanted effects that might occur after the treatment. They will also look at whether the treatment might help improve behavior, communication skills, and quality of life related to digestive symptoms, although the main focus is on safety.
During the study, children will receive the cell treatment and will be closely watched for any reactions or side effects. The study team will use questionnaires to measure changes in daily living skills, communication abilities, and how digestive problems affect quality of life. All children in this study will receive the treatment, as this is an open label study, meaning everyone knows what treatment is being given.
Denmark 
